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Abstract. Malignant melanomas are characterized by a high
intrinsic resistance to chemotherapy. Multiple drug resistance
(MDR) can be mediated by transport proteins such as MDR-1,
multidrug resistance-associated protein (MRP) or lung
resistance protein (LRP). The cytotoxic analogue of somato-
statin AN-238 consisting of 2-pyrrolinodoxorubicin (AN-201)
linked to a somatostatin analogue RC-121 binds to receptors
for somatostatin and is targeted to tumors expressing these
receptors. We evaluated the expression of somatostatin
receptors on human malignant melanoma tumor lines MRI-
H255 and MRI-H187 and examined the effects of the targeted
analogue AN-238 and its cytotoxic radical AN-201 on growth
of these tumors in nude mice. We also studied the effects of
AN-238 and AN-201 on the expression of MDR-1, MRP-1 and
LRP by real-time PCR. AN-238 inhibited the growth of MRI-
H255 and MRI-H187 tumors while AN-201 was ineffective.
Blockade of somatostatin receptors by somatostatin analogue
RC-121 abolished the effects of AN-238. Targeted therapy
with AN-238 did not produce an induction of mRNA of
MDR-1, MRP-1 or LRP. Our findings show that targeted
chemotherapy with cytotoxic somatostatin analogue AN-238
inhibits the growth of malignant melanomas. AN-238 could
provide a novel treatment approach for advanced malignant
melanomas.
Introduction
In the past four decades, the incidence of malignant melanoma
has increased steadily. Currently, melanoma ranks as the fifth
most common cancer among men in the US and sixth in
women with an estimated 60,000 new cases in both sexes in
2005 (1). When diagnosed early, melanoma can be cured by
wide surgical excision. However, metastatic disease remains
generally incurable with a median survival time of 7.5 months
and a five-year survival rate of 5.5% (2). Various therapeutic
modalities are available for the treatment of metastatic
melanoma including surgical resection of metastatic lesions
(3,4), chemotherapy with dacarbazine (DTIC) (5,6) and
immunotherapy with tumor cell vaccines (4,7,8) as well as
biological response modifiers (9,10). Although promising
clinical results were reported, no improvement in overall
survival was achieved during the past 22 years (2). Thus, novel
more effective treatment strategies are needed.
The elucidation of molecular characteristics of malignant
cells prompted the development of a new class of drugs known
as targeted therapeutics. These include inactivators of genes or
gene products involved in oncogenesis, antibodies against
tumor surface structures and conjugates consisting of tumor-
specific ligands linked to toxins, radionuclides or chemo-
therapeutic agents (11-14). Targeted chemotherapy can be
based on peptide hormone ligands, which directly deliver the
cytotoxic agents to tumor cells expressing the corresponding
receptors (15,16). Since binding sites for somatostatin have
been detected on various malignant cells (17), we developed
a cytotoxic somatostatin analogue, AN-238, consisting of the
somatostatin carrier octapeptide RC-121 (D-Phe-Cys-Tyr-D-
Trp-Lys-Val-Cys-Thr-NH2) linked covalently to a highly
potent derivative of doxorubicin (DOX), 2-pyrrolino-DOX
(AN-201). AN-238 binds with high affinity to somatostatin
receptor subtypes 2 and 5 (sst2 and sst5) and with medium
affinity to sst3 (15). In experimental models of tumors
expressing somatostatin receptors, targeted therapy with
AN-238 induces a substantially greater tumor inhibition than
the non-targeted radical AN-201 (18-23).
Receptors for somatostatin were found in a high percentage
of malignant melanomas with 96% of the tumors expressing
sst1, 83% sst2, 61% sst3, 57%, sst4 and 9% sst5 (24). In clinical
studies, radiolabeled SST analogues were successfully used to
detect metastatic lesions of malignant melanomas (25,26).
Consequently, receptors for SST on malignant melanomas
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could be used for targeted therapy with the cytotoxic somato-
statin analogue AN-238.
Metastatic malignant melanomas are highly resistant to a
wide variety of chemotherapeutic agents. Multiple drug
resistance (MDR) of tumor cells can be mediated by several
proteins with different mechanisms of action. P-glycoprotein
(Pgp), the product of the MDR-1 gene and the recently
discovered MDR related protein 1 (MRP-1) increase the
cellular efflux of chemotherapeutic drugs (27), while vault
proteins, such as lung resistance protein (LRP), are involved in
the drug transport from the nucleus to the cytoplasma (28,29).
LRP protein has been detected in human specimens of
malignant melanomas with the highest expression in
metastatic tissue exposed to chemotherapy (30). Targeted
chemotherapy leads to an increased concentration of the
chemotherapeutic agent in the malignant tissue and treatment
with cytotoxic analogues such as AN-238 could overcome
MDR caused by drug transport proteins.
In the current study, we evaluated the antitumor activity of
the cytotoxic somatostatin analogue AN-238 in two models
of human malignant melanomas xenografted into nude mice.
In addition, we examined the effects of AN-238 and its non-
targeted cytotoxic radical (AN-201) on the expression levels
of MDR-1, MRP-1 and LRP.
Materials and methods
Peptides and cytotoxic agents. The somatostatin octapeptide
carrier RC-121 (D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-
NH2) and cytotoxic radical AN-201 were synthesized in our
laboratory as described (31,32). AN-238 was made by coupling
AN-201-14-O-hemiglutarate to the NH2 terminus of [Lys-(N-
(9-fluorenyl) methoxycarbonyl)5] RC-121, followed by
deprotection and purification (33). Before the i.v. injection,
the compounds were dissolved in 20 μl of 0.01 N aqueous
acetic acid and diluted with 5% (w/v) aqueous D-mannitol
solution (Sigma, St. Louis, MO) to the final volume.
Tumor lines. The two transplantable human melanoma tumor
lines MRI-H255 and MRI-H187 were obtained as frozen tumor
tissues from the National Cancer Institute (Frederick Cancer
Research and Development Center, MD). Thawing and trans-
plantation procedures were carried out as recommended.
Animals. Five- to six-week-old female athymic nude mice
(Ncr nu/nu) were obtained from the National Cancer Institute
(NCI, Bethesda, MD, USA). The animals were housed in
sterile cages under laminar flow hoods in a temperature-
controlled room with a 12-h light/12-h dark schedule and were
fed autoclaved chow and water ad libitum.
Experimental protocol. Tumors resulting 8 weeks after trans-
plantation in donor animals were aseptically dissected and
mechanically minced. Pieces of tumor tissue (~3 mm3) were
transplanted subcutaneously (s.c.) into the experimental animals
by a trocar needle. Tumor volume (length x width x height x
0.5236) and body weight were measured weekly. At the end
of each experiment, mice were sacrificed under anaesthesia,
tumors were excised and weighed and necropsy was performed.
Tumor specimens were snap frozen and stored at -70˚C. All
experiments were in accordance with the institutional guide-
lines for the welfare of animals in experiments.
Experiment 1. Mice-bearing MRI-H255 melanomas with a
mean tumor volume of 100 mm3 were assigned to three
groups of 9 animals each. The animals received the following
treatment as a single injection into the jugular vein: Group 1,
control, vehicle solution (5% mannitol); group 2, cytotoxic
analogue AN-238 at a dose of 250 nmol/kg; group 3, cyto-
toxic radical AN-201 at a dose of 250 nmol/kg. The experiment
was terminated on day 22.
Experiment 2. Animals with MRI-H255 tumors with a mean
tumor size of about 50 mm3 were divided into six groups and
received the following treatment on day 1 and day 15: Group 1,
control, vehicle solution (10 mice); group 2, AN-238 at
200 nmol/kg (10 mice); group 3, AN-201 at 200 nmol/kg
(10 mice); group 4, the carrier RC-121 at a dose of 200 nmol/
kg (5 mice); group 5, unconjugated mixture of the cytotoxic
radical AN-201 and the carrier RC-121 at a dose of 200 nmol/
kg (5 mice); group 6, 200 μg of RC-121 i.v. 15 min prior to the
i.v. injection of cytotoxic analogue AN-238 at 200 nmol/kg
(5 mice). The experiment was terminated after 28 days.
Experiment 3. Animals bearing MRI-H187 melanomas were
assigned to three groups of 10 mice each when tumors had
reached a size of 60-70 mm3 and received the following
treatment as i.v. injections on day 1: Group 1, control, vehicle
solution; group 2, AN-238 at 200 nmol/kg; group 3, AN-201
at 200 nmol/kg. The experiment was terminated on day 22.
Evaluation of toxicity. General toxicity was evaluated on the
bases of total leukocyte count (WBC), loss of body weight and
macroscopic changes of somatostatin receptor-bearing organs.
WBC was determined with the Unopette microcollection kit
(Becton Dickinson, Franklin Lakes, NJ) before and seven days
after the drug administration. Body weights were measured
weekly. Somatostatin receptor-bearing organs such as brain,
gastrointestinal tract and kidneys were weighed and examined
during necropsy.
RNA isolation and reverse transcription (RT) PCR. Total
RNA was extracted from tumors by using the TRI-Reagent®
kit (Sigma-Aldrich Co., St. Louis, MO, USA), following the
manufacturer's instructions. RNA was subjected to RT using
the RNA PCR core kit (Applied Biosystems, Norwalk, CT,
USA) according to the manufacturer's instructions. RNA (1 μg)
was transcribed into cDNA in a final volume of 20 μl. All PCR
reactions were performed in an Applied Biosystems PCR
system 2700 (Applied Biosystems, Norwalk, CT, USA). For
amplification of cDNA transcripts, gene-specific primers for
somatostatin receptors 1-5 (sst1-5) were used as described in
detail (34,35). A total RNA negative control which contained
water in the RT reaction was used to rule out genomic DNA
contamination. PC-3 human androgen independent human
prostate cancer served as a positive control.
Western immunoblot analysis. For immunodetection of sst2 and
sst5, an extraction of membrane proteins from untreated
MRI-H255 and MRI-H187 was performed as reported (36-38).
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The presence of sst2 and sst5 receptor protein was then
demonstrated by Western blotting using two goat polyclonal
human sst2 and sst5 antibodies at a dilution of 1:250 (Santa
Cruz Biotechnology, Santa Cruz, CA), as described (38).
Receptor-binding assay. Binding characteristics of somato-
statin receptors on tumor membrane preparation of control
animals in both melanoma tumor lines were evaluated by
ligand competition assay using 125I-labeled somatostatin
octapeptide RC-160, as described previously (34,35). The
Ligand PC computerized curve-fitting program was used to
determine the type of receptor binding, the dissociation
constant (Kd), and the maximal binding capacity (Bmax) of
receptors (34,35).
Real-time PCR for MDR-1, LRP and MRP mRNA expression.
Total RNA was isolated from ~100 mg of tumor tissue for
each sample according to the TRI-Reagent protocol. Total
RNA (1 μg) was subjected to reverse transcription with the
Iscript cDNA synthesis kit (BioRad) following the
manufacturer's protocol. Real-time PCR was employed to
measure drug resistance gene expression using the SYBR
Green system (BioRad). Primers for MDR-1 (sense 5'-TCT
GGA GGA AGA CAT GAC CAG GTA-3'; antisense 5'-GGC
ACC AAA ATG AAA CCT GAA TGT-3'), MRP-1 (sense
5'-AGA GAC AGC TCA GCA GCT CCT-3'; antisense 5'-
GCC TTG TCA GCC TCC ATC AG-3'), LRP (5'-ATCATT
CAGGCCACCATCATCAG-3'; antisense 5'-AACACCG
CTGGGAGGTACG-3') and ß-actin (sense 5'-CTG GAA
CGG TGA AGG TGA CA-3'; antisense 5'-AAG GGA CTT
CCT GTA ACA ATG CA-3') were used to measure gene
expression. The thermal cycling conditions comprised an
initial denaturation step at 95˚C for 3 min, then 40 cycles of
two-step PCR including 95˚C for 15 sec and 60˚C for 1 min.
Data were collected during the 60˚C annealing step and were
further analyzed by the i-Cycler iQ optical system software
(Bio-Rad). Real-time PCR efficiencies (E) for MDR-1 (target
gene 1), MRP (target gene 2) and ß-actin (reference gene)
were calculated from the given slopes in the iCycler software
according to the following equation: E=10[-1/slope] (39). Three
tumor samples from experiment 2 and 3 (control, the AN-238
and the AN-201 group) were analyzed in triplicates. For the
mathematical model used in this study it was necessary to
determine the crossing points for the transcripts of each sample.
Crossing points (CPs) are defined as the number of cycles at
which the fluerescense rises appreciably above the background
fluorescence. Using CP deviations (ΔCP) for control and
treatment (CPcontrols-CPtreatment) of target and reference gene
transcripts, quantification of the target genes in treated groups
relative to the controls was performed using a mathematical
model by Pfaffl (40):
Ratio = (Etarget)ΔCP target (control-treatment): (Ereference)(ΔCP reference (control-treatment)
Statistical analysis. Data are expressed as means ± SE.
Differences between mean values were evaluated by 2-tailed
Student's t-test. p<0.05 was considered significant.
Results
Effects of treatment with cytotoxic AN-238 on tumor growth
in vivo. In experiment 1, a single administration of AN-238 at
250 nmol/kg significantly (p<0.05) inhibited the growth of
human MRI-H255 melanoma resulting in a 68.4% reduction
of tumor volume compared to the controls. Tumor weight
was also significantly (p<0.05) reduced by 64.6% and tumor
doubling time was significantly prolonged as compared to
control animals. Equimolar doses of the cytotoxic radical
AN-201 had no significant effects on any tumor growth
characteristics (Fig. 1 and Table I).
In experiment 2, administration of AN-238 at 200 nmol/kg
on day 1 and day 15 significantly reduced the tumor volume
of MRI-H255 melanomas from day 8 until the end of the
experiment on day 29, the final tumor volume being 71.1%
smaller than in the controls (p<0.001). Mean tumor weight was
also significantly (p<0.001) decreased by 68.3%. Equimolar
doses of the cytotoxic radical AN-201, a mixture of AN-201
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Figure 1. Effects of targeted cytotoxic somatostatin analogue AN-238 and
its radical AN-201 on the growth of MRI-H255 human malignant melanoma
xenografted into nude mice. Arrow indicates treatment, *p<0.05 vs. controls.
Figure 2. Effects of targeted cytotoxic somatostatin analogue AN-238, the
radical AN-201, the carrier somatostatin analogue RC-121, a mixture of
AN-201 and RC-121, and AN-238 after receptor blockade with a high dose
of somatostatin analogue RC-121 on the growth of MRI-H255 human
malignant melanoma xenografted into nude mice. Arrow indicates treatment,
*p<0.05 vs. controls.
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and somatostatin analogue RC-121 or carrier RC-121 alone had
no significant effects on any tumor growth characteristics.
The effect of AN-238 could be blocked by injecting 200 μg
of the somatostatin analogue RC-121, 15 min prior to the
administration of AN-238 (Fig. 2 and Table I).
In experiment 3, a single dose of AN-238 at 200 nmol/kg
significantly reduced tumor volume of MRI-H187 melanomas
from day 8 until the end of the experiment on day 22 (Fig. 2)
when the final tumor volume was 66.6% (p<0.001) smaller
than in the control group. Tumor weights in the group treated
with AN-238 were 64.0% (p<0.001) lower than in controls and
tumor doubling time was significantly (p<0.001) extended.
AN-201 had no significant effects on tumor growth (Fig. 2
and Table I).
Side effects and toxicity. In all treatment groups, except for the
carrier group, a slight, reversible loss of body weight was
observed 8 days after therapy, which ranged from 0.5-5.7%
in the AN-238 groups and from 4.1-11.4% in the AN-201
groups. In experiment 1, body weights in the AN-201 group
were significantly decreased on day 8 (p<0.01) and on day 15
(p<0.01), as compared to controls. In experiment 2, body
weights were significantly (p<0.05) reduced on days 8, 15 and
22 in the AN-201 group and in groups that received the
mixture- and the blockade. No significant loss of body weight
was observed after treatment with AN-238 (Fig. 3).
WBC was measured before and seven days after the
injections. AN-238 did not significantly decrease the WBC
in any of the three studies. However, AN-201 significantly
(p<0.05) suppressed WBC on day 8 in all experiments. In
experiment 2, the measurement prior to the second injection
showed that the WBC was still significantly (p<0.05) below the
normal range. A further decrease was found seven days after
the second administration of AN-201.
Macroscopical or significant changes in organ weights
were detected in somatostatin receptor-bearing organs were
not observed in any of the experiments. One mouse died in the
control group on day 5 in experiment 1. In experiment 2, one
animal died on day 8 in the AN-201 group and one on day 26
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Table I. Effects of therapy with cytotoxic somatostatin analogue AN-238, the cytotoxic radical AN-201, the carrier RC-121,
an unconjugated mixture of AN-201 and RC-121, and AN-238 after blockade of the receptors with RC-121 on the growth of
human melanomas MRI-H255 and MRI-H187 xenografted in nude mice.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Tumor volume [mm3] Tumor doubling time Tumor weight [mg]
Treatment Initial final (% inhibition) [days] (% inhibition)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Experiment 1: MRI-H255
Control 107.4±29.7 1578.0±377.2 5.4±0.3 2212.5±638.7
AN-238 97.0±20.8 498.9±113.3a (68.4) 8.9±0.8b 783.8±247.9 (64.6)a
AN-201 103.6±21.6 1180.5±190.8 (25.2) 6.2±0.4 1695.0±489.3 (23.4)
Experiment 2: MRI-H255
Control 53.4±7.6 1790.0±226.1 5.7±0.2 2074.0±244.3
AN-238 52.3±4.4 517.4±83.3c (71.1) 9.3±0.7c 658.2±106.7c (68.3)
AN-201 52.2±5.2 1958.6±177.7 (-9.4) 5.4 ± 0.2 2231.9±221.5 (-7.6)
Carrier 50.9±10.9 1966.1±588.1 (-9.8) 5.5±0.4 2298.2±684.8 (-10.8)
Mixture 51.1±8.1 2148.1±454.5 (-20.0) 5.4±0.3 2760.8±573.2 (-33.1)
Blockade 51.0±6.2 1572.4±171.6 (12.2) 5.7±0.1 1594.1±151.7 (23.1)
Experiment 3: MRI-H187
Control 70.3±7.9 1058.8±113.8 5.7±0.2 1448.6±144.4
AN-238 62.4±8.2 364.4±37.8c (66.6) 8.9±0.8c 521.3±58.8c (64.0)
N-201 63.4±8.4 805.0±114.0 (24.0) 6.1±0.2 1144.4±146.6 (21.0)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ap<0.05 vs. controls; bp<0.01 vs. controls; cp<0.001 vs. controls.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Effects of targeted cytotoxic somatostatin analogue AN-238 and
its radical AN-201 on the growth of MRI-H187 human malignant melanoma
xenografted into nude mice. Arrow indicates treatment, *p<0.05 vs. controls.
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in the AN-207 group. In experiment 3, one mouse died in the
AN-201 group on day 17.
Expression and characteristics of somatostatin receptors.
Using gene-specific primers, mRNA expression for all five
receptor subtypes was found in both human melanoma tumor
lines with the expected size of 217 bp for sst1, 1104 bp for sst2a,
183 bp for sst3, 278 bp for sst4 and 222 bp for sst5 (Fig. 4A).
The presence of sst2 and sst5 receptor protein in untreated
MRI-H255 and MRI-H187 tumors was evaluated by Western
blotting using specific antibodies. Specific bands showing
two 43 kd proteins for sst2 and sst5 protein were found in all
investigated tumor samples (Fig. 4B).
Ligand competition assays showed a single class of high
affinity-binding sites for somatostatin in membranes of MRI-
H255 and MRI-H187 human melanomas with a mean
dissociation constant (Kd) of 3.69±0.2 nM in MRI-H255
tumors and 8.68±0.4 nM in MRI-H187 tumors. The mean
maximal-binding capacities (Bmax) were 321.8±4.9 fmol/mg
membrane protein in MRI-H255 tumors and 505.9±5.9 fmol/
mg membrane protein in MRI-H187 tumors, respectively.
MDR-1 and MRP-1 and LRP mRNA expression by real-time
PCR. mRNA for MDR-1, MRP-1 and LRP was detected in
both cell lines (Fig. 5). The PCR products were of the expected
sizes of 95 bp for MDR-1, 127 bp for MRP-1, 143 bp for LRP
and 140 bp for ß-actin (Fig. 5). The efficiencies (E) were 1.989
for MDR-1, 1.999 for MRP-1, 2.050 for LRP and 1.997 for
ß-actin. In MRI-H187 tumors, treatment with AN-201 caused
a 3.78- and 1.69-fold induction of mRNA of MDR-1 and LRP,
respectively; while no upregulation of MDR-1 or LRP was
found after injection of AN-238. MRP-1 was not altered in
either treatment group. In MRI-H255 tumors, therapy with
AN-238 or AN-201 was not associated with major changes in
mRNA expression for MDR-1, LRP and MRP-1 (data not
shown).
Discussion
Malignant melanomas are characterized by their high intrinsic
resistance to conventional chemotherapy. After standard
therapy with dacarbazine, the response rates of patients with
metastatic melanoma are as low as 11-28% and a complete
tumor regression occurs in only 4% of the cases (5,41). Other
treatment approaches, such as combination chemotherapy
based on various drugs and the recently introduced cytotoxic
agent, temozolomide were not superior to the standard therapy
(8,42,43). Chemoresistance of neoplastic cells can be caused by
different MDR proteins such as the transport proteins MDR-1
and MRP-1 that mediate drug efflux from tumor cells and
LRP, which is involved in the transport of chemotherapeutic
agents from the nucleus to the cytoplasma. Targeted chemo-
therapy was developed to increase the intratumoral concen-
tration of cytotoxic radicals by a more selective drug delivery
to malignant cells. This novel therapeutic approach results in
a higher antitumor efficacy and may overcome MDR based on
efflux proteins.
Somatostatin receptors are expressed in a high percentage
of human malignant melanomas specimens (24). Accordingly,
mRNA for all five subtypes of somatostatin receptors and
specific-binding sites for a radiolabeled somatostatin analogue
were detected in human MRI-H255 and MRI-H187 mela-
nomas. The targeted cytotoxic somatostatin analogue AN-238
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Figure 4. (A) Expression of mRNA for somatostatin receptor subtypes 1-5
in human malignant melanomas MRI-H255 and MRI-H187 as revealed by
RT-PCR. PCR products were separated on a 1.8% agarose gel and stained
with ethidium bromide. mRNA expression for all five receptor subtypes was
found with the expected size of 217 bp for sst1, 1104 for sst2a, 183 for sst3,
278 for sst4 and 222 for sst5, in both human malignant melanoma tumor lines.
Lanes 1-3, MRI-H255; lanes 4-6, MRI-H187; -, negative control; +, positive
control (PC-3 human prostate carcinoma). (B) Expression of sst2a and sst5
protein as revealed by Western blot analysis. The receptor proteins were at
the expected sizes of 43 kd (sst2a) and 43 kd (sst5) kd. Lanes 1-3 are MRI-
H255 tumors; lanes 4-6, MRI-H187 tumors; +, positive control (PC3 human
prostate cancer).
Figure 5. Expression of mRNA for MDR-1, MRP-1 and LRP in malignant
melanomas as revealed by RT-PCR. PCR products were separated on a
1.8% agarose gel and stained with ethidium bromide. Specific bands with
the expected of 95 bp for MDR-1, 127 bp for MRP-1 and 143 bp for BCRP
were found in both human malignant melanoma tumor lines. Lanes 1-2,
MRI-H255 tumors; lanes 3-4, MRI-H187 tumors; -, negative control; +,
positive control (A498 human renal cell cancer for MDR-1; H460 non-small
cell human lung carcinoma for MRP-1 and LRP).
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significantly inhibited the growth of both MRI-H255 and
MRI-H187 melanomas xenografted into nude mice, resulting
in a 66.6-71.1% reduction in tumor volume and significantly
prolonged the tumor doubling time in all experiments. Equi-
molar doses of the cytotoxic radical AN-201 did not affect any
growth parameter. The carrier peptide, somatostatin analogue
RC-121 or a mixture of AN-201 and RC-121 did not suppress
the growth of MRI-H255 tumors, indicating that the effect
of AN-238 is not due to the hormonal activity of the carrier
octapeptide RC-121, but rather to its ability to deliver
conjugated AN-201 to cancerous cells. The inhibitory effects
of AN-238 on tumor growth could be abolished by blocking
the tumoral somatostatin receptors with an excess of the
somatostatin analogue RC-121. This result further supports
the targeting concept.
In the current study, the toxicity of cytotoxic somatostatin
analogue AN-238 and its radical AN-201 was evaluated with
respect to mortality, loss of body weight and WBC and effects
on somatostatin receptor-expressing organs. In all three
experiments, only one animal died after the administration of
AN-238, two animals after the injection of AN-201, and one
death also occurred in a control group. Loss of body weight
was observed in all treatment groups as compared to controls
except for animals that received the carrier alone. However, in
mice treated with AN-238 loss of weight was less severe and
animals regained weight faster than those receiving AN-201.
No macroscopic changes or weight differences were found
in somatostatin receptor-positive organs. Myelotoxicity is
considered the most serious side-effect and the dose-limiting
factor of chemotherapy. In our study, AN-238 did not
significantly reduce WBC at any time, while eight days after
the injection of AN-201 a significant decrease in WBC was
found in all three experiments. Some of the systemic toxicity
observed in this study, including a loss of body weight and a
minor decrease of WBC after administration of AN-238, may
be caused by a high esterase activity in mouse serum, which
cleaves the ester bond of AN-238 and releases AN-201 in the
circulation (44). However, serum esterase activity is much
lower in humans than in mice (44). Therefore, it can be
assumed that toxicity of AN-238 in patients would be further
decreased. In previous studies, we demonstrated a significant
reduction in toxicity of AN-238 in mice pretreated with an
esterase inhibitor (44,45). Accordingly, in preliminary studies
with radiolabeled somatostatin analogues, no or only low
toxicity was observed in patients, at doses causing objective
therapeutic responses (46-48).
Recent in vitro findings suggest that targeted therapy
with the cytotoxic LHRH analogue AN-152 may delay the
development of resistance to chemotherapy in endometrial
cancer (49). In our study, only cytotoxic radical AN-201, but
not targeted cytotoxic somatostatin analogue AN-238 caused
some induction of MDR-1 and LRP in MRI-H187 tumors. In
MRI-H255 melanomas, no major changes of MDR-1 and
LRP were found after administration of either compound. No
induction of mRNA for MRP-1 occurred after treatment with
AN-238 or AN-201. Thus, a rapid development of chemo-
resistance by targeted chemotherapy should not be expected.
In conclusion, our results demonstrate that cytotoxic
somatostatin analogue AN-238 significantly inhibits growth
of somatostatin receptor-positive human melanoma tumors.
AN-238 was more efficacious and less toxic than its radical
AN-201. Consequently, the use of AN-238 could provide a
novel and effective approach to the treatment of patients with
metastatic melanomas.
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